Molecular therapy intervention prospects in prostate cancer

Current Pharmaceutical Design

Volumn 10, Issue 5, 2004, Pages 523-530

  Rege, Yashraj D ^a   Rangnekar, Vivek M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Genes; Molecular therapy; Par 4; Prostate cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INDUCING FACTOR; CALCIUM ION; CASPASE 8; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTOMYCIN B; NIFEDIPINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4; STAUROSPORINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; WORTMANNIN;

APOPTOSIS; CALCIUM CELL LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CAUSE OF DEATH; CELL PROLIFERATION; EPITHELIUM CELL; FREQUENCY ANALYSIS; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; REGULATORY MECHANISM; REVIEW; TISSUE SPECIFICITY; UNITED STATES; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; GENE THERAPY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS;

EID: 1042280304     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453234     Document Type: Review

References (95)

1. Sawyer, TK. Cancer - emerging breakthrough drugs. Biotechniques 2001; 30(3), 626-632.
2. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28:251-265.
3. Isaacs JT, Lundmo PI, Berger R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992; 13: 457-464.
4. Denmeade SR, Tombal B, Isaacs JT. Programmed Cell Death, Volume II: Advances in Cell Aging and Gerontology, Vol 6, Elsevier B.V., Amsterdam, Netherlands. 2001, pp 23-54.
5. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms Nat Rev Mol Cell Biol 2001;2:589-598.
6. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
7. Hengartner MO. The biochemistry of apoplosis. Nature 2000; 407: 770-776.
8. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-633.
9. Martikainen P, Kyprianou N, Tucker R, Isaacs JT. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res 1991; 51: 4693-4700.
10. Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001; 20(3-4), 225-243.
11. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768.
12. Wertz IE, Dixit VM. Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells. J Biol Chem 2000; 275: 11470-11477.
13. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994; 54: 6167-6175.
14. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997; 33:201-207.
15. Sells SF, Wood DP Jr, Joshi-Barve SS, MuthukumarS, Jacob RJ, Crist SA, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994; 5: 457-466.
16. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284:555-556.
17. McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997; 239:357-366.
18. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
19. Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995; 270: 11962-11969.
20. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80:285-291.
21. Knudson CM, Korsmeyer SJ. (1997) Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997; 16: 358-363.
22. Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. (1988) Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988;336:259-261.
23. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-6060.
24. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53:4701-4714.
25. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997; 91: 627-637.
26. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, et al. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 1997; 57: 3115-3120.
27. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
28. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
29. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 1997; 272: 30299-30305.
30. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56: 4743-4748.
31. Bruckheimer EM, Gjertsen BT, McDonnell TJ. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 1999; 26: 382-398.
32. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157: 569-574.
33. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-4445.
34. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-398.
35. Rokhlin OW, Guseva N, Tagiyev A, Knudson CM, Cohen MB. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 2001; 20: 2836-2843.
36. Marcelli M, Marani M, Li X, Sturgis L, Haidacher SJ, Trial JA, et al. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate 2000; 42: 260-273.
37. Li X, Marani M, Mannucci R, Kinsey B, Andriani F, Nicoletti I, et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001; 61: 1699- 1706.
38. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470: M55-M62.
39. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-4197.
40. Palayoor ST, Yournell MY, Calderwood SK, Coleman CN. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394.
41. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272:14914-14920.
42. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014.
43. Khwaja A. Akt is more than just a Bad kinase. Nature 1999; 401:33-34.
44. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
45. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 2001; 276: 38361-38369.
46. Murillo H, Huang H, Schmidt LJ, Smith DJ, Tindall DJ. Role of P13K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-4805.
47. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
48. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/ PTEN. Cancer Res 1999; 59: 2551-2556.
49. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246-5250.
50. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 1996; 56: 2157-2160.
51. Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001; 276:27740-27744.
52. Yu EY, Yu E, Meyer GE, Brawer MK. The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic carcinoma. Prostate Cancer Prostatic Dis 1997 Sep; 1 (1):39-44.
53. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
54. Lecane PS, Kiviharju TM, Sellers RG, Peehl DM. Leptomycin B stabilizes and activates p53 in primary prostatic epithelia] cells and induces apoptosis in the LNCaP cell line. Prostate 2003; 54(4): 258-67.
55. Bowen C, Voeller HJ, Kikly K, Gelmann EP. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death Differ 1999; 6: 394-401.
56. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fas1 to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001; 61: 7255-7263.
57. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, et al. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 1997; 17: 3823-3832.
58. El-Guendy N, Rangnekar VM. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 2003; 1; 283(1): 51-66.
59. Yin XM, Oltavi ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369 (6478), 321-323.
60. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335 (6189), 440-442.
61. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, et al. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996; 86(5), 777-786.
62. Page G, Kogel D, Rangnekar V, Scheidtmann KH. Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 1999; 18(51), 7265-7273.
63. Chang S, Kim JH, Shin J. p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4-induced PKCzeta inhibition. FEBS Lett 2002; 510(1-2), 57-61.
64. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996; 16(12), 6945-6956.
65. Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999; 274(42), 29976-29983.
66. Qiu SG, Krishnan S, El-Guendy N, Rangnekar VM. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 1999; 18(50) 7115-7123.
67. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 1999; 18(22), 6362-6369.
68. Diaz-Meco MT, Lallena MJ, Monjas A, Frutos S, Moscat J. Inactivation of the inhibitory kappaB protein kinase /nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem 1999; 274(28), 19606-19612
69. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389:191-194.
70. Berra E, Municia MM, Sanz L, Frutos S, Diaz-Meco MT, Moscat J. Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol Cell Biol 1997; 17(8), 4346-4354.
71. Sanz-Navares E, Fernandez N, Kazanietz MG, Rotenberg SA. Atypical protein kinase Czeta suppresses migration of mouse melanoma cells. Cell Growth Differ 2001; 12(10), 517-524.
72. Gilmore TD. The Rel/NF-kappa B signal transduction pathway: introduction. Oncogene 1999; 18(49), 6842-6844.
73. Baeuerle PA and Baltimore D. NF-kappa B: ten years after Cell 1996; 87(1), 13-20.
74. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18(49), 6938-6947.
75. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387(6635), 773-776.
76. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296(5573), 1635-1636.
77. Butler J, Rangnekar VM. Par-4 for molecular therapy of prostate cancer. Current Drug Targets 2003; 4(3): 223-30.
78. Harrison GS, Glode LM. Current challenges of gene therapy for prostate cancer. Oncology 1997; 11(6), 845-856; discussion 856-861.
79. Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum Gene Ther 1996; 7(9), 1123-1129.
80. Lattime CE, Gerson LS. Gene Therapy of Cancer 2002; 2nd ed., Academic Press. pp. 534.
81. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274(5286), 373-376.
82. Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 1999; 6(6), 499-504.
83. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Therapy 1995; 2(6), 357-362.
84. Ficazzola MA, Taneja SS. Prospects for gene therapy in human prostate cancer. Mol Med Today 1998; 4(11), 494-504.
85. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87(6), 2211-2215.
86. Prince HM. Gene transfer: a review of methods and applications. Pathology 1998; 30(4), 335-347.
87. Hickman MA, Malone RW, Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, et al. Gene expression following direct injection of DNA into liver. Hum. Gene Ther 1994; 5(12) 1477-1483.
88. Sikes ML, O'Malley BW Jr, Finegold MJ, Ledley FD. In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum Gene Ther 1994; 5(7), 837-844.
89. Hersh EM, Akporiaye E, Harris D, Stopeck AT, Unger EC, Warneke JA, et al. Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Hum Gene Ther 1994; 5(11), 1371-1384.
90. Nabel GJ, Chang AE, Nabel EG, Plautz GE, Ensminger W, Fox BA, et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5(1), 57-77.
91. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990; 87(24), 9568-9572.
92. Tamura T, Sakata T. Application of in vivo electroporation to cancer gene therapy. Curr Gene Ther 2003; 3(1): 59-64.
93. Adjei AA. Ras signaling pathway proteins as therapeutic targets. Curr Pharm Design 2001; 7(16): 1581-94.
94. Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, et al. Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Design 2002; 8(22): 1945-58.
95. Vuckovic S, Clark GJ, Hart DN. Growth factors, cytokines and dendritic cell development. Curr Pharm Design 2002; 8(5): 405-18.